Navigation Links
Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
Date:10/5/2007

FRANKLIN, Mass., Oct. 5 /PRNewswire-FirstCall/ -- Following its recent merger with Echo Therapeutics, Inc., Sontra Medical Corporation (OTC Bulletin Board: SONT), a dual platform-enabled transdermal specialty therapeutics and diagnostics company, today announced that it has changed its corporate name to Echo Therapeutics, Inc., effective Monday, October 8, 2007. In addition, on October 8, 2007, the Company's OTC Bulletin Board ticker symbol will change to "ECTE" and its corporate website address will become http://www.echotx.com.

"Our new name better reflects our expanded strategic focus on building a broad pipeline of advanced topical formulations of FDA-approved specialty pharmaceutical products and next generation needle-free transdermal diagnostics," said Patrick T. Mooney, M.D., CEO of Echo Therapeutics.

About Echo Therapeutics

Echo Therapeutics is a dual platform-enabled, specialty therapeutics and diagnostics company developing an extensive pipeline of advanced topical formulations of FDA-approved products and a suite of needle-free transdermal diagnostics. Echo is developing a next generation, needle-free Continuous Transdermal Glucose Monitor (CTGM) system for use in the diabetes home care and hospital critical care markets. Echo's next generation CTGM system leverages its FDA-approved SonoPrep(R) ultrasound-mediated skin permeation technology platform. Echo is also developing a broad portfolio of advanced topical formulations of well-established, FDA-approved products using its proprietary AzoneTS(TM) dermal penetration technology. Echo has submitted a New Drug Application (NDA) to the FDA for the approval of its lead Azone TS- based product, Durhalieve(TM), for the treatment of corticosteroid responsive dermatoses.

SonoPrep is a registered trademark of Echo Therapeutics, Inc.

Any statements contained in this press release that do not describe historical facts may consti
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Check if your “Favourite medical web-site” is indulging in Quackey
2. Teens turning to Internet for medical queries
3. Robots craft medical history
4. NBE to conduct test for medical students from abroad
5. Air pollution combined with greater medical needs
6. Indian Nationals with Foreign Medical Degrees can now practice in India
7. Children! Protecting them from medical mistakes
8. More information sought by patients on medical errors
9. SARS necessitates medical masks
10. Meditation Works Medically
11. Sleep Disorders Could Indicate Other Medical Problems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2008)...esults of a 10-year study published in the August ...found that magnesium sulfate administered to women...he risk of cerebral palsy by 50 percent. The Benef...) trial was conducted in 18 centers in the U.S., i...renatal intervention ever found to reduce the inst...
(Date:8/29/2008)... http://www.aronowitzmd.com [Los An...espected experience in plastic surgery procedures ...consideration may be necessary for these patients,...e an established specialty of procedures for after...es, CA (PRWEB) August 29, 2008 -- Bariatric surger...
(Date:8/28/2008)...ues increase 138% versus Q2 2007 - Nine new Cen...RNewswire-FirstCall/ - CRH Medical Corporation,(CR... three and six months,ended June 30, 2008 (all fig...ths ended June 30, 2008 increased 138% to $1,653,8...7. Revenue for the six months ended June,30, 2008 ...
(Date:8/28/2008)...ion will be based in the Northeast region with mor...xt year, HARRISBURG, Pa., Aug. 28 /PRNewswire-USN...ity has hired a Patient Safety Liaison for the,Nor...eport to the,Pennsylvania Patient Safety Reporting...ylvania citizens., "Last year in focus groups wit...
Breaking Medicine News(10 mins):Health News:National study shows magensium sulfate reduces risk of cerebral palsy in premature births 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 4Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3
...has been little research about the physical activi...ts are exercising and what // they are doing could...ograms for asthma patients. Doctors from the Cente...nducted a study to look at the physical activity l...
...suffering from back pain, pelvic pressure, frequen...could be to blame. Fibroids are non-cancerous // g...rom very small to the size of a cantaloupe or larg...ne fibroid embolization -- a treatment that’s beco...
...tis is a common health problem worldwide. Both ost...ain and stiffness in patients.There is no cure for...maged cartilage. // A new study could help lead do...t of arthritis. The research pinpoints the molecul...
...study finds angioplasty should be the treatment of...pital they initially go to doesn’t offer angioplas...nother facility for treatment. Research has shown ...hey are treated with angioplasty to open up the cl...
Other Medicine News:
(Date:8/27/2008)...tients in the VELCADE, melphalan and prednisone ar... well as a 30 percent complete response -, CAMBRI...e Takeda,Oncology Company today announced the publ...d, Phase III VISTA(1) trial in this week,s edition...ts showed a significant survival,benefit and a 30 ...
(Date:8/27/2008)...First Phase 3 data, from BLISS-52 trial, expected ...LISS-76, expected by fall 2009 -, ROCKVILLE, Md.,...iences, Inc. (Nasdaq: HGSI ) today announced it h...S-76, the second of two pivotal Phase 3,randomized... patients with,active systemic lupus erythematosus...
(Date:8/26/2008)...IANAPOLIS, Aug. 26 /- Semafore Pharma...national Congress on Targeted Therapies,in Cancer ...ovel,multi-targeted kinase inhibitors that demonst...l studies., A novel and proprietary molecular sca...ing allowing for the design of pan-PI3 kinase inhi...
(Date:8/26/2008)...LO PARK, Calif., Aug. 26 /-... the positive one-year follow-up data,from the CUS...e of the,peer-reviewed journal, EuroIntervention. ...tella, M.D., of University Medical Center Utrecht,...II Investigators from 13 clinical,sites across Eur...
Breaking Medicine Technology:New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 2New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 4New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 5New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 6Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 2Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 4Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 5Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 6Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 2Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 2XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 4Blood pressure drug telmisartan shows powerful activity against stroke 1570 1Blood pressure drug telmisartan shows powerful activity against stroke 1570 2Blood pressure drug telmisartan shows powerful activity against stroke 1570 3Ireland Cancer Center researchers advance stem cell gene therapy 1565 1Ireland Cancer Center researchers advance stem cell gene therapy 1565 2Ireland Cancer Center researchers advance stem cell gene therapy 1565 3Wind power explored off Californias coast 1563 1Wind power explored off Californias coast 1563 2Wind power explored off Californias coast 1563 3Wind power explored off Californias coast 1563 4Ceregene Presents Long term Follow up From Phase 1 Trial of CERE 120 in Parkinsons Disease 1050 1Ceregene Presents Long term Follow up From Phase 1 Trial of CERE 120 in Parkinsons Disease 1050 2Ceregene Presents Long term Follow up From Phase 1 Trial of CERE 120 in Parkinsons Disease 1050 3Ceregene Presents Long term Follow up From Phase 1 Trial of CERE 120 in Parkinsons Disease 1050 4
The PachPen uses state-of-the-art waveform analysis and a probe that samples at a 65MHz rate to obtain precise readings. The PachPen stores and averages nine measurements and calculates IOP correctio
...ailable as both regular and filter tips. Sterilize...re efficient sterilization and are delivered with ...e of irradiation. Sterilized Diamond Tips are read...k Diamond Tips are wrapped in medical device quali...
300 L, Bulk Recommended for 250 and 300 L pipettes.
Ambion's barrier tips prevent cross-contamination of samples by means of an aerosol filter. They are RNase- and DNase-free and are ideal for handling RNA, PCR applications, and for working with radio
Medicine Products: